This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Staffeldt, B. Articles by Roots, I. Search for Related Content PubMed PubMed Citation Articles by Staffeldt, B. Articles by Roots, I. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Antidepressants Hazardous Substances DB PERYLENE QUERCETIN Social Bookmarking                         What's this?

Pharmacokinetics of Hypericin and Pseudohypericin After Oral Intake of the Hypericum Perforatum Extract LI 160 in Healthy Volunteers

R. Kerb

J. Brockmöller

M. Ploch

I. Roots

The single- and multiple-dose pharmacokinetics of the naphthodianthrones hypericin and pseudohypericin derived from St. John's wort (Hypericum perforatum, LI 160, Lichtwer Pharma GmbH, Berlin) were studied in 12 healthy male subjects. After a single oral dose of 300, 900, or 1800 mg of dried hypericum extract (250, 750, or 1500 µg hypericin and 526, 1578, or 3156 µg pseudohypericin), plasma levels were measured with a modified highly sensitive high-pressure liquid chromatography (HPLC) method (lower detection limit 0.1 ng/mL) up to 3 days. The median maximal plasma levels were 1.5, 4.1, and 14.2 ng/mL for hypericin and 2.7, 11.7, and 30.6 ng/mL for pseudohypericin, respectively, for the three doses given above (interim evaluation of four volunteers). The median elimination half-life times of hypericin were 24.8 to 26.5 hours, and varied for pseudohypericin from 16.3 to 36.0 hours. Ranging between 2.0 to 2.6 hours, the median lag-time of absorption was remarkably prolonged for hypericin when compared to pseudohypericin (0.3 to 1.1 hours). The areas under the curves (AUC) showed a nonlinear increase with raising dose; this effect was statistically significant for hypericin. During long-term dosing (3 x 300 mg/day), a steady-state was reached after 4 days. Mean maximal plasma level during the steady-state treatment was 8.5 ng/mL for hypericin and 5.8 ng/mL for pseudohypericin, while mean trough levels were 5.3 ng/mL for hypericin and 3.7 ng/mL for pseudohypericin. In spite of their structural similarities there are substantial pharmacokinetic differences between hypericin and pseudohypericin. (J Geriatr Psychiatry Neurol 1994; 7(suppl 1): S47-S53).

Journal of Geriatric Psychiatry and Neurology, Vol. 7, No. 1, S47-S53 (1994)
DOI: 10.1177/089198879400700113


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				S. Zhou, E. Chan, S.-Q. Pan, M. Huang, and E. J. D. Lee Pharmacokinetic Interactions of Drugs with St John's Wort J Psychopharmacol, June 1, 2004; 18(2): 262 - 276. [Abstract] [PDF]

				Final Report on the Safety Assessment of Hypericum Perforatum Extract and Hypericum Perforatum Oil International Journal of Toxicology, January 1, 2001; 20(2_suppl): 31 - 39. [Abstract] [PDF]

				G. Harrer and V. Schulz Clinical Investigation of the Antidepressant Effectiveness of Hypericum J Geriatr Psychiatry Neurol, October 1, 1994; 7(1): S6 - S8. [Abstract] [PDF]

				H.-M. Thiede and A. Walper Inhibition of MAO and COMT by Hypericum Extracts and Hypericin J Geriatr Psychiatry Neurol, October 1, 1994; 7(1): S54 - S56. [Abstract] [PDF]